Information Provided By:
Fly News Breaks for June 28, 2017
SUPN
Jun 28, 2017 | 05:55 EDT
Jefferies analyst David Steinberg raised his price target for Supernus Pharmaceuticals to $51 from $45 after conducting a survey of high prescribing physicians to gauge their views on Trokendi XR post the recent launch in migraine prophylaxis. The surveyed clinicians anticipate treating 26.6% of their severe migraine patients with Trokendi within five years post launch, Steinberg tells investors in a research note. This suggests theoretical Trokendi migraine revenue of $960M, or roughly two times the current consensus, the analyst points out. He keeps a Buy rating on Supernus.
News For SUPN From the Last 2 Days
There are no results for your query SUPN